Type 2 Diabetes Mellitus in Youth

Chapter
First Online:

Abstract

Type 2 diabetes, once considered a disease restricted to adults, has increased in prevalence in childhood, largely due to the obesity epidemic in youth. This disease represents a serious public health issue as it is associated with significant comorbidities and complications even when compared with adults with the same disease and children with type 1 diabetes. Presently, metformin and insulin are the only two medications approved for use in children and little is known about the prevention of type 2 diabetes in youth. There is an urgent need for a better understanding of the underlying biology of the disease in youth and for the development of effective preventative and therapeutic strategies.

Keywords

Type 2 diabetes Obesity Insulin resistance Lifestyle intervention Metformin Insulin 
This is a preview of subscription content, log in to check access

Notes

Acknowledgments

Modified from previous edition version by Cosimo Giannini M.D., Ph.D. and Sonia Caprio M.D.

References

  1. 1.
    SEARCH Study Group. SEARCH for Diabetes in Youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Control Clin Trials. 2004;25(5):458–71.CrossRefGoogle Scholar
  2. 2.
    Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care. 2012;35(12):2515–20.CrossRefGoogle Scholar
  3. 3.
    Narasimhan S, Weinstock RS. Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. Mayo Clin Proc. 2014;89(6):806–16.CrossRefGoogle Scholar
  4. 4.
    Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36(12):3863–9.CrossRefGoogle Scholar
  5. 5.
    Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159–67.CrossRefGoogle Scholar
  6. 6.
    Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778–86.CrossRefGoogle Scholar
  7. 7.
    Lee JM. Why young adults hold the key to assessing the obesity epidemic in children. Arch Pediatr Adolesc Med. 2008;162(7):682–7.CrossRefGoogle Scholar
  8. 8.
    Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146(5):693–700.CrossRefGoogle Scholar
  9. 9.
    Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care. 2005;28(8):1876–81.CrossRefGoogle Scholar
  10. 10.
    Harron KL, Feltbower RG, McKinney PA, Bodansky HJ, Campbell FM, Parslow RC. Rising rates of all types of diabetes in south Asian and non-south Asian children and young people aged 0-29 years in West Yorkshire, U.K., 1991-2006. Diabetes Care. 2011;34(3):652–4.CrossRefGoogle Scholar
  11. 11.
    Praveen PA, Kumar SR, Tandon N. Type 2 diabetes in youth in South Asia. Curr Diab Rep. 2015;15(2):571.CrossRefGoogle Scholar
  12. 12.
    Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46(4):701–10.CrossRefGoogle Scholar
  13. 13.
    Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247–56.CrossRefGoogle Scholar
  14. 14.
    Liu LL, Lawrence JM, Davis C, Liese AD, Pettitt DJ, Pihoker C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes. 2010;11(1):4–11.CrossRefGoogle Scholar
  15. 15.
    Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. Diabetologia. 1981;20(2):87–93.CrossRefGoogle Scholar
  16. 16.
    Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima indians: contributions of obesity and parental diabetes. Am J Epidemiol. 1981;113(2):144–56.CrossRefGoogle Scholar
  17. 17.
    Lee ET, Howard BV, Savage PJ, Cowan LD, Fabsitz RR, Oopik AJ, et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45-74 years. The Strong Heart Study. Diabetes Care. 1995;18(5):599–610.CrossRefGoogle Scholar
  18. 18.
    Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes. 2000;49(12):2201–7.CrossRefGoogle Scholar
  19. 19.
    Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981–90.CrossRefGoogle Scholar
  20. 20.
    Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46(3):234–44.CrossRefGoogle Scholar
  21. 21.
    Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579–89.CrossRefGoogle Scholar
  22. 22.
    Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, Frossard P, et al. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet. 2011;43(10):984–9.CrossRefGoogle Scholar
  23. 23.
    Cho YS, Chen CH, Hu C, Long J, Ong RT, Sim X, et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet. 2012;44(1):67–72.CrossRefGoogle Scholar
  24. 24.
    Steinthorsdottir V, Thorleifsson G, Sulem P, Helgason H, Grarup N, Sigurdsson A, et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat Genet. 2014;46(3):294–8.CrossRefGoogle Scholar
  25. 25.
    Ma RC, Hu C, Tam CH, Zhang R, Kwan P, Leung TF, et al. Genome-wide association study in a Chinese population identifies a susceptibility locus for type 2 diabetes at 7q32 near PAX4. Diabetologia. 2013;56(6):1291–305.CrossRefGoogle Scholar
  26. 26.
    Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747–53.CrossRefGoogle Scholar
  27. 27.
    Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care. 2000;23(3):381–9.Google Scholar
  28. 28.
    Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996;128(5 Pt 1):608–15.CrossRefGoogle Scholar
  29. 29.
    Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136(5):664–72.CrossRefGoogle Scholar
  30. 30.
    Ciaraldi TP, Aroda V, Mudaliar S, Chang RJ, Henry RR. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab. 2009;94(1):157–63.CrossRefGoogle Scholar
  31. 31.
    Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab JPEM. 2005;18(9):865–72.CrossRefGoogle Scholar
  32. 32.
    Zeitler P, Haqq A, Rosenbloom A, Glaser N. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. J Pediatr. 2011;158(1):9–14, e1-2.CrossRefGoogle Scholar
  33. 33.
    American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2016;39(Suppl 1):S13–22.Google Scholar
  34. 34.
    Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24(3):447–53.CrossRefGoogle Scholar
  35. 35.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefGoogle Scholar
  36. 36.
    Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care. 2011;34(6):1306–11.CrossRefGoogle Scholar
  37. 37.
    Buse JB, Kaufman FR, Linder B, Hirst K, El Ghormli L, Willi S. Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. Diabetes Care. 2013;36(2):429–35.CrossRefGoogle Scholar
  38. 38.
    Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci. 2008;1150:256–9.CrossRefGoogle Scholar
  39. 39.
    Klingensmith GJ, Pyle L, Arslanian S, Copeland KC, Cuttler L, Kaufman F, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care. 2010;33(9):1970–5.CrossRefGoogle Scholar
  40. 40.
    Dabelea D, Pihoker C, Talton JW, D’Agostino RB Jr, Fujimoto W, Klingensmith GJ, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth study. Diabetes Care. 2011;34(7):1628–33.CrossRefGoogle Scholar
  41. 41.
    Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH. Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes. 2007;8(2):53–9.CrossRefGoogle Scholar
  42. 42.
    (11) Children and Adolescents. Diabetes Care. 2016;39(Supplement 1):S86–93.Google Scholar
  43. 43.
    Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364–82.CrossRefGoogle Scholar
  44. 44.
    Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60(5):1552–60.CrossRefGoogle Scholar
  45. 45.
    Rascati K, Richards K, Lopez D, Cheng LI, Wilson J. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database. Diabetes Obes Metab. 2013;15(10):901–5.CrossRefGoogle Scholar
  46. 46.
    Academy of Nutrition and Dietetics’ Pediatric Weight Management Evidence-Based Nutrition Practice Guidelines. http://www.andevidencelibrary.com/topiccfm?cat=4102&auth=1.
  47. 47.
    Berry D, Urban A, Grey M. Management of type 2 diabetes in youth (part 2). J Pediatr Health Care. 2006;20(2):88–97.CrossRefGoogle Scholar
  48. 48.
    Loghmani ES. Nutrition therapy for overweight children and adolescents with type 2 diabetes. Curr Diab Rep. 2005;5(5):385–90.CrossRefGoogle Scholar
  49. 49.
    McGavock J, Sellers E, Dean H. Physical activity for the prevention and management of youth-onset type 2 diabetes mellitus: focus on cardiovascular complications. Diab Vasc Dis Res. 2007;4(4):305–10.CrossRefGoogle Scholar
  50. 50.
    National Heart, Lung, and Blood Institute, US Department of Health and Human Services; National Institute of Health. Reduce screen time. www.nhlbi.nih.gov/health/public/heart/obesity/wecan/reduce-screen-time/index.htm.
  51. 51.
    Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9):1898–906.CrossRefGoogle Scholar
  52. 52.
    Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22(6):925–7.CrossRefGoogle Scholar
  53. 53.
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–18.CrossRefGoogle Scholar
  54. 54.
    Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30(4):790–4.CrossRefGoogle Scholar
  55. 55.
    Karres J, Pratt V, Guettier JM, Temeck J, Tamborlane WV, Dunger D, et al. Joining forces: a call for greater collaboration to study new medicines in children and adolescents with type 2 diabetes. Diabetes Care. 2014;37(10):2665–7.CrossRefGoogle Scholar
  56. 56.
    Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014;149(7):707–15.CrossRefGoogle Scholar
  57. 57.
    Inge TH, Miyano G, Bean J, Helmrath M, Courcoulas A, Harmon CM, et al. Reversal of type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics. 2009;123(1):214–22.CrossRefGoogle Scholar
  58. 58.
    Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36(6):1735–41.Google Scholar
  59. 59.
    Mayer-Davis EJ, Ma B, Lawson A, D’Agostino RB Jr, Liese AD, Bell RA, et al. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. Metab Syndr Relat Disord. 2009;7(2):89–95.CrossRefGoogle Scholar
  60. 60.
    Springer SC, Silverstein J, Copeland K, Moore KR, Prazar GE, Raymer T, et al. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics. 2013;131(2):e648–64.CrossRefGoogle Scholar
  61. 61.
    Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36(6):1758–64.Google Scholar
  62. 62.
    Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, Imperatore G, Williams DE, Bell RA, et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2006;29(8):1891–6.CrossRefGoogle Scholar
  63. 63.
    Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710–38.CrossRefGoogle Scholar
  64. 64.
  65. 65.
    Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92(1):78–82.PubMedGoogle Scholar
  66. 66.
    Laffel L, Chang N, Grey M, Hale D, Higgins L, Hirst K, et al. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes. 2012;13(5):369–75.CrossRefGoogle Scholar
  67. 67.
    Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (Baltimore, Md). 2008;48(1):119–28.CrossRefGoogle Scholar
  68. 68.
    Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther. 2008;30(6):1168–76.CrossRefGoogle Scholar
  69. 69.
    Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–68.CrossRefGoogle Scholar
  70. 70.
    Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care. 2013;36(6):1772–4.Google Scholar
  71. 71.
    Mayer-Davis EJ, Davis C, Saadine J, D’Agostino RB Jr, Dabelea D, Dolan L, et al. Diabetic retinopathy in the SEARCH for Diabetes in Youth Cohort: a pilot study. Diabet Med. 2012;29(9):1148–52.CrossRefGoogle Scholar
  72. 72.
    Maahs DM, Snively BM, Bell RA, Dolan L, Hirsch I, Imperatore G, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2007;30(10):2593–8.CrossRefGoogle Scholar
  73. 73.
    Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728–35.CrossRefGoogle Scholar
  74. 74.
    Levitt Katz L, Gidding SS, Bacha F, Hirst K, McKay S, Pyle L, et al. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. Pediatr Diabetes. 2015;16(1):39–47.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Pediatric Endocrinology and DiabetesUniversity of California at San FranciscoSan FranciscoUSA
  2. 2.Division of Pediatric Endocrinology and Pediatric Diabetes CenterMassachusetts General HospitalBostonUSA
  3. 3.Department of PediatricsHarvard Medical SchoolBostonUSA

Personalised recommendations